All In Biotech

Drug Trial Radar · NCT02023697

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

A Three Arm Randomized, Open-label Phase II Study of Radium-223 Dichloride 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) Versus 80 kBq/kg (88 kBq/kg After Implementation of NIST Update), and Versus 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) in an Extended Dosing Schedule in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone

Last checked: Nov 20, 2026Latest source record: Jul 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 391 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

391

Actual

Start

Mar 10, 2014

Primary completion

Mar 1, 2017

Study completion Aug 9, 2018

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Dec 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases documented within 8 weeks of randomization. Subjects will be randomized to one of 3 treatment arms in a 1:1:1 fashion: a standard regimen of radium-223 dichloride of 50 kBq/kg (55 kBq/kg after implementation of NIST update) injections every month for 6 months, a high dose regimen of 80 kBq/kg (88 kBq/kg after implementation of NIST update)injections every month for 6 months or an extended duration regimen of 50 kBq/kg (55 kBq/kg after implementation of NIST update) injections every month for 12 months. Following the treatment phase, subjects will be followed up every 12 weeks for a minimum of 2 years, at which point they will enter a long term follow-up period during which they are seen every 6 months for up to 7 years after the last dose of radium dichloride. Symptomatic skeletal event and safety endpoints will be assessed at each clinic visit. Pain and analgesic use data will be collected every 4 weeks through Week 48. Additionally, radiological assessments including MRI/CT of the abdomen and pelvis and chest CT, as well as technetium-99 bone scans will be performed at Weeks 8, 16, and 24 and continue every 12 weeks thereafter until disease progression is documented in either the bone or in soft tissue. Radiological imaging will be evaluated by blinded central review.

Conditions

  • Prostatic Neoplasms

Interventions

  • Radium-223 dichloride (Xofigo, BAY88-8223)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard DoseTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
  2. Symptomatic Skeletal Event-Free Survival - High Dose vs. Standard DoseTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
  3. Number of Participants With an Event Defining SSE Free Survival - Extended Dose vs. Standard DoseTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
  4. Symptomatic Skeletal Event-Free Survival - Extended Dose vs. Standard DoseTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
  5. Number of Participants With an Event Defining SSE Free Survival - Three Dose Groups As RandomizedTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)
  6. Symptomatic Skeletal Event Free Survival - Three Dose Groups As RandomizedTime frame: From randomization to 135 SSE-FS events have been observed in comparison 1 or 75 SSE-FS events observed in comparison 2, whichever occurred last (approximately 36 months from first patient randomization)

Locations

68 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Scottsdale, Arizona

  • Site not named

    New Haven, Connecticut

  • Site not named

    Fort Myers, Florida

  • Site not named

    Bethesda, Maryland

  • Site not named

    Rockville, Maryland

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    East Setauket, New York

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Box Hill, Australia

  • Site not named

    Darlinghurst, Australia

  • Site not named

    Westmead, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Melbourne, Victoria, Australia

  • Irmandade Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto do Câncer do Estado de São Paulo

    São Paulo, São Paulo, Brazil

  • IBCC - Instituto Brasileiro de Controle do Cancer

    São Paulo, São Paulo, Brazil

  • Hospital Israelita Albert Einstein

    São Paulo, São Paulo, Brazil

  • Site not named

    London, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Santiago, Chile

  • Site not named

    Chomutov, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Nantes, France

  • Site not named

    Vandœuvre-lès-Nancy, France

  • Site not named

    Villejuif, France

  • Site not named

    Tübingen, Baden-Wurttemberg, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Dresden, Saxony, Germany

  • Site not named

    Beersheba, Israel

  • Site not named

    Haifa, Israel

  • Site not named

    Jerusalem, Israel

  • Site not named

    Kfar Saba, Israel

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.